Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000306405 | SCV000340875 | uncertain significance | not provided | 2016-04-27 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000332343 | SCV000459340 | uncertain significance | Retinitis Pigmentosa, Recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000306405 | SCV001197768 | likely benign | not provided | 2025-01-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002521967 | SCV003532134 | uncertain significance | Inborn genetic diseases | 2021-07-20 | criteria provided, single submitter | clinical testing | The c.1405G>A (p.E469K) alteration is located in exon 11 (coding exon 10) of the MAK gene. This alteration results from a G to A substitution at nucleotide position 1405, causing the glutamic acid (E) at amino acid position 469 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |